
|Articles|May 6, 2010
Avastin/Lucentis controversy continues
"Why was Lucentis, at $2000 per dose chosen for the study, rather than Avastin at $50 per dose?? so asked Irv Arons in his blog spot.
Advertisement
“As I read the news release from the NEI/NIH yesterday morning, about the one-year results of the clinical trial evaluating the combination use of Lucentis with pan-retinal laser therapy to treat diabetic macular oedema, prior to posting it online, and later, when I read the complete study as posted in Ophthalmology, the one thought that kept running through my mind was, why was Lucentis, at $2000 per dose chosen for the study, rather than Avastin at $50 per dose?” so said Irv Arons in his blog spot.
What do you think? Tell us at
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
FLORetina-ICOOR 2026: AI moves from the image to the trial, the clinic, and the operating room
2
BL1332 misses primary end point in phase 2 post-PRK ocular pain study
3
Water-soluble CBD eye drops lower IOP and dampen corneal sensitivity in glaucoma mouse model
4
Q&A: GLP-1 RAs and NAION, the case for a baseline exam
5











